Serum levels of long pentraxin PTX3 in patients with polymyalgia rheumatica.

Abstract

OBJECTIVES:

To evaluate PTX3 feasibility to provide a prognostic tool in PMR clinical practice.

METHODS:

Circulating PTX3 levels were measured in 93 PMR patients at disease onset and during corticosteroid therapy and in 46 normal controls (NC) by ELISA.

RESULTS:

No difference in PTX3 concentrations was observed between NC and PMR either at disease onset and during follow-up or between groups of patients defined according to the presence of recurrence/relapse.

CONCLUSIONS:

PTX3 serum levels do not increase significantly in active PMR. Further studies on patients with giant-cell arteritis could evaluate whether large vessel involvement may be associated to increased PTX3 levels.

• Authors: L Pulsatelli, G Peri, P Macchioni, L Boiardi, C Salvarani, F Cantini, A Mantovani, R Meliconi
• Journal: Clinical and experimental rheumatology (Clin Exp Rheumatol) Vol. 28 Issue 5 Pg. 756-8 ( 2010) ISSN: 0392-856X [Print] Italy
• PMID: 20822713 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers
• Glucocorticoids
• Serum Amyloid P-Component
• PTX3 protein
• C-Reactive Protein

Topics

• Aged
• Aged, 80 and over
• Biomarkers (blood)
• C-Reactive Protein (analysis)
• Enzyme-Linked Immunosorbent Assay
• Female
• Glucocorticoids (therapeutic use)
• Humans
• Male
• Middle Aged
• Polymyalgia Rheumatica (blood, diagnosis, drug therapy)
• Prognosis
• Prospective Studies
• Recurrence
• Serum Amyloid P-Component (analysis)